Off-the-shelf and on the decline: Adicet Bio’s shares halved after PhI look at cell therapy

Adicet Bio’s stock price was halved on Tues­day morn­ing as in­vestors tanked the biotech’s shares $ACET fol­low­ing a look at Phase I da­ta on its off-the-shelf cell ther­a­py.

The Cal­i­for­nia biotech’s al­lo­gene­ic cell ther­a­py is be­ing in­ves­ti­gat­ed in pa­tients with ag­gres­sive forms of B-cell non-Hodgkin’s lym­phoma, and half of them had pre­vi­ous­ly failed on an au­tol­o­gous CAR-T ther­a­py, a sign that more treat­ment op­tions are need­ed be­yond the first-gen­er­a­tion ap­proach. But Adicet’s da­ta drop af­ter Mon­day’s clos­ing bell — and talk of a lat­er-than-pre­vi­ous­ly guid­ed piv­otal tri­al — sent shares spi­ral­ing and led an­a­lysts to ques­tion the dura­bil­i­ty po­ten­tial of ADI-001.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN